10-Q: Aclarion Q2: Revenue Up, Cash Strong, Losses Widen
Quarterly Report
Aclarion, Inc. reported a significant increase in revenue and cash reserves for Q2 2025, driven by UK market expansion, despite widening net losses and increased operating expenses.
Summary
- Revenue for the three months ended June 30, 2025, increased by 76% to $19,319, up from $10,971 in the prior year period.
- Year-to-date revenue for the six months ended June 30, 2025, grew by 82% to $38,309, compared to $21,085 in the same period of 2024.
- Gross profit improved significantly, reaching $5,140 for Q2 2025 (from a loss of $12,323 in Q2 2024) and $651 for YTD 2025 (from a loss of $21,685 in YTD 2024).
- Net loss for Q2 2025 was $(1,600,757), an increase from $(1,238,077) in Q2 2024.
- Year-to-date net loss for 2025 was $(3,638,193), slightly higher than $(3,637,180) for YTD 2024.
- Operating expenses increased across all categories: Sales and Marketing rose 53% in Q2 and 59% YTD, R&D increased 34% in Q2 and 6% YTD, and G&A grew 62% in Q2 and 37% YTD.
- Cash and cash equivalents significantly increased to $12,850,657 as of June 30, 2025, from $463,661 at December 31, 2024, primarily due to $20.1 million in gross proceeds from recent capital raises.
- Total liabilities decreased to $564,422 as of June 30, 2025, from $1,153,426 at December 31, 2024.
- The company effected two reverse stock splits in 2025: 1:335 on January 30, 2025, and 1:27 on March 28, 2025.
- A $687,500 settlement payment was made in March 2025 related to a 'fee tail' provision of an investment banking agreement.
Sentiment
Score: 5
Explanation: The company shows promising revenue growth and has significantly improved its liquidity through recent capital raises. However, widening net losses, increased operational expenses, and acknowledged material weaknesses in internal controls present notable challenges. The overall sentiment is neutral to slightly positive, reflecting both progress and ongoing risks typical of an early-stage growth company.
Positives
- Revenue increased significantly by 76% in Q2 2025 and 82% year-to-date, primarily driven by growing volume of Nociscan reports in the UK market following local coverage decisions.
- Gross profit turned positive in Q2 2025 ($5,140) and YTD 2025 ($651), a substantial improvement from losses in the prior year periods.
- Cash and cash equivalents surged to $12,850,657 as of June 30, 2025, providing enhanced liquidity.
- Successfully raised $20.1 million in gross proceeds from public and registered direct offerings and warrant exercises during the first six months of 2025.
- Reduced total liabilities by approximately 51% from December 31, 2024, to June 30, 2025.
- Redeemed all Series B Preferred Stock and related accrued dividends with a cash payment of $1,213,590 in January 2025, simplifying the capital structure.
- Converted remaining Series C Preferred Stock into common shares and exercised Series C warrants, further streamlining the capital structure.
- Stockholders approved the full issuance of shares for Series A and B Common Warrants on March 5, 2025, facilitating future warrant exercises.
- Initiated the Clarity trial with the first patient enrolled in June 2025, indicating progress in clinical development.
Negatives
- Net loss widened to $(1,600,757) for Q2 2025, compared to $(1,238,077) for Q2 2024.
- Total operating expenses increased by 55% in Q2 2025 and 35% year-to-date, driven by higher sales and marketing, R&D, and general and administrative costs.
- Cash used in operating activities increased to $(4,376,394) for the six months ended June 30, 2025, from $(3,293,096) in the prior year period, indicating higher cash burn.
- Incurred a $687,500 penalty payment in March 2025 to settle a dispute related to an investment banking agreement.
- Management identified material weaknesses in internal control over financial reporting, including limited segregation of duties and a lack of adequate accounting resources for complex transactions.
Risks
- Limited operating history, which makes it difficult to evaluate the business and future prospects.
- Significant competition from other companies in the healthcare technology sector.
- Dependence on key personnel, with the loss of whom could adversely affect operations.
- Challenges in managing potential rapid growth effectively.
- Inability to guarantee future results or that forward-looking statements will be achieved.
- Need to raise substantial additional funds to continue technology development and commercialization efforts, with no guarantee of availability on acceptable terms.
- Potential for dilution of existing stockholders' ownership interest if additional capital is raised through equity sales.
- Possible restrictive covenants from future debt or preferred equity financing that could limit business operations.
- Risk of relinquishing valuable rights to technology or future revenue streams if funds are raised through licensing or strategic collaborations.
- Cash balances may at times exceed federally insured limits, exposing the company to potential loss.
- Ongoing litigation risks, though current pending matters are not expected to have a material adverse effect.
- Material weaknesses in internal control over financial reporting could lead to material misstatements in financial statements.
Future Outlook
Current cash and cash equivalents are expected to fund operating expenses and capital expenditure requirements into the third quarter of 2026. The company acknowledges the need to raise additional funds to continue funding technology development and commercialization efforts and is actively managing its cash position to secure long-term funding.
Management Comments
- Brent Ness, Chief Executive Officer, and John Lorbiecki, Chief Financial Officer, certified that the report fairly presents the financial condition, results of operations, and cash flows.
- Management concluded that disclosure controls and procedures are not effective due to limited resources, lack of formal control documentation, and a small number of employees.
- Management also identified material weaknesses in internal control over financial reporting due to limited segregation of duties and a lack of adequate accounting resources for complex transactions.
- The company is working with an outside firm to establish best practices to improve internal control over financial reporting.
Industry Context
Aclarion operates in the healthcare technology sector, specializing in magnetic resonance spectroscopy (MRS) and proprietary biomarkers for optimizing clinical treatments. The reported revenue growth, particularly in the UK market, suggests successful penetration and adoption of its Nociscan reports, aligning with a broader trend of increasing demand for advanced diagnostic and treatment optimization technologies. The initiation of the Clarity trial indicates ongoing commitment to clinical validation and product development, a common strategy for medical technology companies seeking market expansion and reimbursement.
Comparison to Industry Standards
- The filing does not provide specific comparable companies, projects, or industry benchmarks to assess Aclarion's performance against global standards. Direct comparisons are limited without detailed competitor financial or operational data within the filing.
- The revenue growth driven by 'local coverage decisions' in the UK market suggests successful navigation of regulatory and reimbursement pathways, which is a critical success factor in the medical technology industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Amendment | Stockholders approved an amendment to the 2022 Aclarion Equity Incentive Plan on December 31, 2024, increasing the number of shares reserved for issuance by 1,500,000 (166 post-2025 Stock Splits) to a total of 1,695,695 (188 post-2025 Stock Splits). | 2024-12-31 | Increases the pool of shares available for equity compensation, potentially aiding in talent retention and incentivization, but also allowing for further dilution. |
| Proposed Equity Incentive Plan Amendment (Not Approved) | A proposed amendment to the 2022 equity incentive plan was not approved at the 2025 Annual Meeting of Stockholders on July 21, 2025. | 2025-07-21 | Indicates shareholder resistance to further expansion of the equity incentive plan beyond the previously approved increase, potentially limiting future share-based compensation flexibility. |
| Reverse Stock Splits | Effected a 1:335 reverse stock split on January 30, 2025, and a 1:27 reverse stock split on March 28, 2025. | 2025-01-30 | Reduced the number of outstanding shares and proportionately increased the per-share value and strike price of warrants/options, typically done to increase share price and maintain Nasdaq listing compliance. This also significantly altered the weighted average shares outstanding for EPS calculations. |
Legal Proceedings
- Paid $687,500 in March 2025 to settle a dispute under the 'fee tail' provision of a previously entered investment banking agreement.
Stakeholder Impact
- Shareholders: Experienced significant dilution from recent capital raises and reverse stock splits. Future equity raises pose further dilution risk. The increase in cash provides a longer runway but at a cost.
- Employees: Bonus accruals were made in Q2 2025, indicating compensation incentives. Share-based compensation is also a component of employee remuneration.
- Customers: Benefit from the growing volume of Nociscan reports, particularly in the UK, indicating increased access to the company's services.
- Creditors: The company reduced its total liabilities and redeemed Series B Preferred Stock, improving its balance sheet position relative to debt obligations.
- Suppliers/Partners: The company continues to incur costs for hosting, software, field support, and UCSF royalty, indicating ongoing relationships.
Next Steps
- Continue funding technology development and commercialization efforts.
- Actively manage cash position and secure long-term funding.
- Continue the Clarity trial, with the first patient enrolled in June 2025.
- Address and remediate material weaknesses in internal control over financial reporting by establishing best practices with an outside firm.
Key Dates
| Date | Description |
|---|---|
| 2022-04-21 | Company's 2022 Aclarion Equity Incentive Plan went into effect. |
| 2023-10-09 | White Lion Equity Line Common Stock Purchase Agreement initiated. |
| 2024-02-27 | Public offering of 5,175,000 units completed, raising approximately $3.0 million gross proceeds. |
| 2024-08-12 | Subscription agreement entered with an institutional investor to sell 400,000 shares of common stock for $116,000 gross proceeds. |
| 2024-08-14 | Exchange agreement entered with accredited investors to exchange $930,052 of debt for 930 shares of newly issued Series B convertible preferred stock. |
| 2024-08-15 | Subscription agreement entered with an institutional investor to sell 425,000 shares of common stock for $116,000 gross proceeds. |
| 2024-08-27 | Subscription agreement entered with accredited investors to sell 1,000,000 shares of common stock for $290,000 gross proceeds, and a warrant purchase agreement was also entered. |
| 2024-09-24 | At-The-Market Issuance Sales Agreement entered with Ascendiant Capital Markets, LLC, to sell up to $10 million of common stock. |
| 2024-09-30 | Securities purchase agreement for Series C Preferred Stock financing completed, raising $1,000,000 gross proceeds and issuing warrants. Exercise price for warrants adjusted to $0.1759 per share. |
| 2024-12-31 | Stockholders approved an amendment to the 2022 Equity Incentive Plan to increase shares reserved for issuance. |
| 2025-01-01 | Automatic increase of 619,499 shares to the 2022 Equity Incentive Plan. |
| 2025-01-03 | Registered direct offering completed, selling 3,380,276 shares of common stock for $0.45 million net proceeds. Sales Agreement with Ascendiant Capital Markets, LLC terminated. |
| 2025-01-15 | Underwritten public offering completed, selling units of common shares, pre-funded warrants, Series A and B Common Warrants for $13.4 million net proceeds. |
| 2025-01-22 | All Series B Preferred Stock and related accrued dividends redeemed with a cash payment of $1,213,590. |
| 2025-01-30 | 1:335 reverse stock split of common stock effected. Another registered direct offering completed, selling 506,803 shares of common stock for $4.4 million net proceeds. |
| 2025-03-05 | Special Meeting of Stockholders convened; stockholders approved the full issuance of shares of common stock issuable upon exercise of Series A and B Common Warrants. |
| 2025-03-28 | 1:27 reverse stock split of common stock effected. |
| 2025-06-30 | End of the quarterly period covered by this report. |
| 2025-07-21 | 2025 Annual Meeting of Stockholders reconvened (originally July 7, 2025). Election of seven directors and ratification of independent registered accounting firm approved; amendment to 2022 equity incentive plan not approved. |
| 2025-08-14 | Date of filing of this Quarterly Report on Form 10-Q. |
Recommendation
holdAclarion demonstrates promising revenue growth and has significantly bolstered its cash position through recent capital raises, providing a longer operational runway. However, the company continues to incur substantial net losses and increased operating expenses, reflecting its early-stage development and investment in growth. The acknowledged material weaknesses in internal controls add a layer of operational risk. Given the mixed financial performance, the speculative nature of early-stage medical technology, and the recent dilution from capital raises, a 'hold' recommendation is appropriate. Investors should monitor progress on clinical trials, continued revenue growth, and remediation of internal control issues before considering further investment.
Keywords
Healthcare Technology, MRS, Magnetic Resonance Spectroscopy, Nociscan, Biomarker, Medical Device, Clinical Trials, SEC Filing, 10-Q, Financial Results, Capital Raise, Stock Split, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.